DT-168 in Keratoplasty Patients With Fuchs Endothelial Corneal Dystrophy

Part of paid clinical trials in Indianapolis, Indiana.

Sponsor
Design Therapeutics, Inc.
Study ID
NCT07024693
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Fuchs
  • Fuchs Endothelial Corneal Dystrophy

Eligibility Criteria

Sex
ALL
Age
30 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • DT-168 — DRUG
    Active

Study Details

The purpose of this study is to evaluate the pharmacodynamics, safety, and tolerability of DT-168 Ophthalmic Solution in pre-keratoplasty patients with Fuchs endothelial corneal dystrophy.

Key Dates

Start date
Jul 30, 2025
Status verified
Dec 2025
Primary completion
Sep 30, 2026
Completion
Dec 31, 2026

Study Design

Enrollment
28 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Active
    Drug: DT-168

Primary Outcome Measure

FECD Biomarkers: Splicing Panel [ Time Frame: Perioperative ]

Central Contacts

Locations (2)

FacilityCityStateZIPSite coordinators
DTX-168-201 Study SiteIndianapolisIndiana46260-
DTX-168-201 Study SiteGrand RapidsMichigan49546-

Find similar trials in Indianapolis, IN

By research site
DTX-168-201 Study Site· Indianapolis, INDTX-168-201 Study Site· Grand Rapids, MI

Related Studies